MetLife: Morgan Stanley Lowers PT to $94 from $98, Maintains Overweight Rating.

MetLife: Morgan Stanley Lowers PT to $94 from $98, Maintains Overweight Rating.

Morgan Stanley has revised its price target for MetLife, Inc. (NYSE:MET) from $98 to $94, while maintaining an "overweight" rating on the stock. The update comes after MetLife's recent earnings report, which showed an earnings per share (EPS) of $2.02, falling short of the $2.32 consensus estimate. Revenue for the quarter was also down 2.7% year-over-year, totaling $17.34 billion [1].

Despite the earnings miss, Morgan Stanley believes the company's fundamentals remain strong. The brokerage cited MetLife's robust financial position and the potential for future growth as reasons for maintaining an overweight rating. The $94 price target suggests a 35.08% upside from the current price, indicating Morgan Stanley's bullish outlook on the stock.

The move by Morgan Stanley aligns with a broader trend among analysts. While Wells Fargo increased its price target to $97, UBS reduced its target to $91. The average price target across multiple analysts stands at $96.00, with a consensus rating of "Moderate Buy" [2].

References

[1] https://www.marketbeat.com/instant-alerts/filing-aberdeen-group-plc-acquires-78069-shares-of-metlife-inc-nysemet-2025-08-16/
[2] https://www.marketbeat.com/instant-alerts/jefferies-financial-group-increases-metlife-nysemet-price-target-to-10300-2025-08-11/